Histone deacetylases (HDACs) are evolutionary conserved enzymes which operate by
removing acetyl groups from histones and other protein regulatory factors, with functional …

This review classifies drug‐design strategies successfully implemented in the development
of histone deacetylase (HDAC) inhibitors, which have many applications including cancer …

Histone deacetylases (HDACs) play a crucial role in the remodeling of chromatin, and are
involved in the epigenetic regulation of gene expression. In the last decade, inhibition of …

Histone deacetylases (HDACs) are epigenetic enzymes which participate in transcriptional
repression and chromatin condensation mechanisms by removing the acetyl moiety from …

Malaria, schistosomiasis and leishmaniases are among the most prevalent tropical parasitic
diseases and each requires new innovative treatments. Targeting essential parasite …

Histone deacetylase 8 (HDAC8), a unique class I zinc-dependent HDAC, is an emerging
target in cancer and other diseases. Its substrate repertoire extends beyond histones to …

Current therapies for human parasite infections rely on a few drugs, most of which have
severe side effects, and their helpfulness is being seriously compromised by the drug …

A mini library of HDAC inhibitors with peptoid-based cap groups was synthesized using an
efficient multicomponent approach. Four compounds were identified as potent HDAC6 …

Malaria drug discovery has shifted from a focus on targeting asexual blood stage parasites,
to the development of drugs that can also target exo-erythrocytic forms and/or gametocytes …

Chagas disease, caused by Trypanosoma cruzi, still affects millions of people around the
world. No vaccines nor treatment for chronic Chagas disease are available, and …